ASO-mediated reading frame correction via induced skipping of symmetrical exons has shown promise in the FDA-approved ASOs targeting PTCs in Duchenne’s muscular dystrophy (48) and also in preclinical studies in mice for the treatment of diseases such as CLN3 Batten (49). The gene discussed is CLN3; the disease is Duchenne muscular dystrophy.